Boehringer Ingelheim GmbH, of Boehringer, Germany, presented results from the phase III VIVACITO study at the American Thoracic Society meeting in San Diego, showing that the fixed-dose combination of tiotropium and olodaterol, delivered via the Respimat inhaler, demonstrated a statistically significant improvement over both monotherapy treatment (p < 0.0001) and placebo (p < 0.0001) in the primary endpoint, defined as the forced expiratory volume in one second.